Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

44.64 -0.80 (-1.76%)
Streaming Delayed Price Updated: 1:52 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen (QGEN) Q3 2025 Earnings Call Transcript ↗
Qiagen (QGEN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
From QIAGEN N.V.
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
A Look at Qiagen's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. (NYSE:QGEN) Passes the Caviar Cruise Quality Investment Screen ↗
QIAGEN NV exemplifies the Caviar Cruise investing method with strong sales growth, a 46% ROIC, and robust cash flow, signaling a high-quality business. 
Via Chartmill
News headline image
QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
Illumina's BioInsight Launch Sparks Optimism, Signals New Era for Genomic Data and AI
San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
From QIAGEN N.V.
Via Business Wire
News headline image
DoorDash To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. (NYSE:QGEN) - A Strong Technical Setup for Breakout Investors ↗
QIAGEN N.V. (NYSE:QGEN) shows strong technicals and a high-quality breakout setup, making it a candidate for momentum traders. The stock trades near 52-week highs with clear support and resistance... 
Via Chartmill
News headline image
QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
From QIAGEN N.V..
Via Business Wire
News headline image
QIAGEN N.V. (NYSE:QGEN) – A Quality Stock Worth Considering ↗
QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid cash flow conversion, making it a candidate for long-term investors. 
Via Chartmill
News headline image
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
From QIAGEN N.V.
Via Business Wire
News headline image
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism ↗
Stifel also upgraded the stock to ‘Buy’ with a $107 price target. 
Via Stocktwits
News headline image
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. (NYSE:QGEN) – A Quality Stock with Strong Fundamentals ↗
QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid financial health, making it a candidate for long-term investors. 
Via Chartmill
News headline image
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN announces plans for transition in leadership of Supervisory Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.